140 related articles for article (PubMed ID: 6329511)
1. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
2. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
3. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
4. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
Green MR; Vosika G; Propert KJ; Ware JH; Comis R
Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
6. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
[No Abstract] [Full Text] [Related]
8. Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
[No Abstract] [Full Text] [Related]
10. [Polychemotherapy of small-cell bronchopulmonary cancer. The advantages of adding the selective cytostatic Riaval].
Păunescu E; Dănălache-Dumitrescu M; Oprişiu G; Smărăndache M; Stoinescu M; Vasile DI; Zaharescu C; Burnea D; Claiciu I; Ghinescu V
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1986; 35(3):233-42. PubMed ID: 3027860
[No Abstract] [Full Text] [Related]
11. Phase II trial of bisantrene in advanced colorectal carcinoma.
Ahmed T; Kemeny NE; Michaelson RA; Harper HD
Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
[No Abstract] [Full Text] [Related]
12. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
13. Phase II trial of bisantrene in patients with metastatic melanoma.
Mackel C; Meyskens FL; Alberts DS
Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
[No Abstract] [Full Text] [Related]
14. Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
Conley BA; Hornedo J; Abrams J; Eisenberger M; Hiponia D; Aisner J; Van Echo DA
Cancer Treat Rep; 1987 Sep; 71(9):861-2. PubMed ID: 3040246
[No Abstract] [Full Text] [Related]
15. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
McGuire WP; Blough RR; Cobleigh MA; Johnson CM; Kukla LJ; Lad TE; Lanzotti VJ; Stiff PJ; Zawila P
Cancer Treat Rep; 1983 Sep; 67(9):841-2. PubMed ID: 6883363
[No Abstract] [Full Text] [Related]
17. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of bisantrene in non-small cell lung cancer.
Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung.
Fuks JZ; Van Echo DA; Aisner J; Von Hoff D; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):133-4. PubMed ID: 6261947
[No Abstract] [Full Text] [Related]
20. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]